Male Hormonal Contraception: Where Are We Now?

被引:0
作者
Christina Wang
Mario P. R. Festin
Ronald S. Swerdloff
机构
[1] Harbor-UCLA Medical Center,Clinical and Translational Science Institute, Los Angeles Biomedical Research Institute
[2] World Health Organization,UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development, and Research Training in Human Reproduction
[3] Harbor-UCLA Medical Center,Division of Endocrinology, Department of Medicine
关键词
Male contraception; Androgens; Progestins; Spermatogenesis suppression; Contraceptive efficacy;
D O I
10.1007/s13669-016-0140-8
中图分类号
学科分类号
摘要
Hormonal male contraception clinical trials began in the 1970s. The method is based on the use of exogenous testosterone alone or in combination with a progestin to suppress the endogenous production of testosterone and spermatogenesis. Studies using testosterone alone showed that the method was very effective with few adverse effects. Addition of a progestin increases the rate and extent of suppression of spermatogenesis. Common adverse effects include acne, injection site pain, mood change including depression, and changes in libido that are usually mild and rarely lead to discontinuation. Current development includes long-acting injectables and transdermal gels and novel androgens that may have both androgenic and progestational activities. Surveys showed that over 50 % of men will accept a new male method and female partners will trust their partner to take oral “male pills.” Partnership between government, nongovernment agencies, academia, and industry may generate adequate interest and collaboration to develop and market the first male hormonal contraception.
引用
收藏
页码:38 / 47
页数:9
相关论文
共 184 条
[1]  
Darroch JE(2013)Trends in contraceptive need and use in developing countries in 2003, 2008, and 2012: an analysis of national surveys Lancet 381 1756-62
[2]  
Singh S(2013)Meeting the unmet need for family planning: now is the time Lancet 381 1696-9
[3]  
Peterson HB(2013)National, regional, and global rates and trends in contraceptive prevalence and unmet need for family planning between 1990 and 2015: a systematic and comprehensive analysis Lancet 381 1642-52
[4]  
Darmstadt GL(2011)Contraceptive failure in the United States Contraception 83 397-404
[5]  
Bongaarts J(2013)Hormonal male contraception: end of a dream or start of a new era? Endocrine 43 535-8
[6]  
Alkema L(2015)Male hormonal contraception: looking back and moving forward Andrology 4 4-12
[7]  
Kantorova V(2010)Hormonal approaches to male contraception Curr Opin Urol 20 520-4
[8]  
Menozzi C(2008)Advances in male contraception Endocr Rev 29 465-93
[9]  
Trussell J(1979)Suppression of human spermatogenesis by depot androgen: potential for male contraception J Steroid Biochem 11 663-70
[10]  
Nieschlag E(1979)The potential for an androgen male contraceptive J Clin Endocrinol Metab 49 520-6